Serine Deprivation Enhances Anti-neoplastic Activity of Biguanides

Simon-Pierre Gravel*3,4, Laura Hulea*1,6, Nader Toban*1,2 Elena Birman2, Marie-José Blouin2, Mahvash Zakikhani2, Yunhua Zhao2, Ivan Topisirovic1,2,4,6,7, Julie St-Pierre3,4,7, Michael Pollak1,2,5,6,7

* These authors contributed equally to this work

1 Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada
2 Segal Cancer Center, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
3 Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada
4 Department of Biochemistry, McGill University, Montreal, Quebec, Canada
5 Division of Cancer Prevention, McGill University, Montreal, Quebec, Canada
6 Department of Oncology, McGill University, Montreal, Quebec, Canada
7 Corresponding authors: michael.pollak@mcgill.ca (M.P.), julie.st-pierre@mcgill.ca (J.S.P.), ivan.topisirovic@mcgill.ca (I.T.)

Running title:
Biguanides and serine depletion.

Keywords:
Serine deprivation, Glycolysis, Biguanides, mTORC1, dietary manipulation, metformin, phenformin

Financial support:
NT is supported by a CIHR/FRSQ training grant FRN 53888 in cancer research.

This work was supported by grants from the Canadian Institutes of Health Research (Grant Number MOP-106603 to Julie St-Pierre and number MOP-115195 to Ivan Topisirovic) and the Terry Fox Foundation (grant number TFF-116128 to Ivan Topisirovic, Julie St-Pierre and Michael Pollak). Julie St-Pierre holds salary support from FRSQ. Ivan Topisirovic is a recipient of CIHR New Investigator Salary Award and “Fonds d'établissement” award of FRQ-S.

No potential conflicts of interest to declare.
Word count: 5,215 words
Total number of figures: 7
Abstract
Metformin, a biguanide widely used in the treatment of type II diabetes, clearly exhibits anti-neoplastic activity in experimental models and has been reported to reduce cancer incidence in diabetics. There are ongoing clinical trials to evaluate its antitumor properties, which may relate to its fundamental activity as an inhibitor of oxidative phosphorylation. Here we show that serine withdrawal increases the anti-neoplastic effects of phenformin (a potent biguanide structurally related to metformin). Serine synthesis was not inhibited by biguanides. Instead, metabolic studies indicated a requirement for serine to allow cells to compensate for biguanide-induced decrease in oxidative phosphorylation by upregulating glycolysis. Furthermore, serine deprivation attenuated the impact of metformin on the relative abundance of metabolites within the citric acid cycle. In mice, dietary restriction of serine reduced serine levels in tumors and significantly enhanced the tumor growth-inhibitory actions of biguanide treatment. Our results define a dietary manipulation that can enhance the efficacy of biguanides as agents that target blunt cancer cell energy metabolism and tumor growth.
Introduction

There is evidence that metformin, like other biguanides, inhibits Complex I of the mitochondrial electron transport chain (1,2). In the liver, this causes energetic stress, resulting in inhibition of hepatic gluconeogenesis and reduction in the hyperglycaemia and hyperinsulemia associated with type II diabetes (3,4). Pharmaco-epidemiologic studies have generated the hypothesis that there are novel indications for metformin in oncology by associating its use for diabetes treatment with reductions in cancer risk and improvements in cancer prognosis (reviewed in (5,6)). These findings led to investigation of metformin in pre-clinical cancer models, most of which demonstrate clear antineoplastic effects which are attributable to direct action on neoplastic cells and/or indirect effects resulting from alterations in the hormonal milieu (2,5-7). However, the methodology employed in some of the pharmaco-epidemiologic studies is controversial (8), and most laboratory models involve drug exposure levels considerably higher than those used in diabetes treatment (9). Thus, it is uncertain if conventional anti-diabetic doses of metformin as a single agent have useful antineoplastic activity, and this possibility is being examined in ongoing clinical trials. However, in view of evidence that biguanides may have multiple mechanisms of action (10-14) and that sensitivity to biguanides varies with tumor characteristics (15-17), nutrient conditions (17,18), and other factors (19,20), it is important to define metabolic conditions that influence the action of biguanides.

Cancer cells are metabolically adapted to meet the bioenergetics and biosynthetic demands of proliferation. Dysregulated metabolism in cancer cells presents potential therapeutic targets (21). Enzymatic imbalance in the metabolism of serine in cancer has been shown almost two decades ago (22), and was confirmed by more recent studies highlighting increased
expression of serine synthesis pathway enzymes in breast cancer and melanoma (23,24). In addition, serine starvation causes decreased proliferation and survival (25,26) and induces metabolic reprogramming by inhibiting glycolysis (25-27). As cancer cells treated with biguanides have a particularly stringent reliance on glycolysis to compensate for the inhibition of mitochondrial ATP production and inhibited glucose carbon flux to the citric acid cycle, we investigated the influence of serine deprivation on the antiproliferative effects of metformin and phenformin.

Methods

Cell lines, tissue culture, viral infections, and lentiviral shRNA silencing and proliferation assays

H1299, A549, MCF10A and PrEC were purchased from and authenticated by ATCC using identifiable short tandem repeat (STR) loci. MC38 were generously provided by Dr. Pnina Brodt (McGill University) and authenticated by her laboratory. H1299 with AMPKα1/2 stable knockdown and control cells were a generous gift from Dr. Russell Jones (McGill University) and authenticated by his laboratory (28). All the cell lines were used within six months of resuscitation. H1299, A549 and MC38 cell lines were cultured in RPMI 1640 with 10%(v/v) FBS (Wisent) and gentamycin. MCF10A were cultured in media supplemented with 10μg/mL insulin, 20ng/mL EGF, 100ng/mL choleratoxin, and 0.5μg/mL hydrocortisone; DMEM/F12 5% FBS media was use for regular cell culture and RPMI 5% dialysed FBS media without serine was used for serine deprivation experiments. Primary Prostate Epithelial Cells (PrEC) were cultured in media supplemented with Prostate Epithelial Cell Growth Kit (ATCC); Prostate Epithelial Cell Basal Medium (ATCC) was used for regular culture, and RPMI media without serine was used for serine deprivation experiments.
Lentiviral vectors were from Sigma. Short hairpin RNA (shRNA) vector accession numbers are: mouse PHGDH (Sigma: TRCN0000041627), the Non-Target shRNA Control (Sigma: SHC002). shRNA vectors were co-transfected into HEK293T cells with the lentivirus packaging plasmids pMD2.G and psPAX2 (Addgene plasmids #12259 and #12260, respectively, provided by the laboratory of Dr. Trono, EPF Lausanne) using Lipofectamine 2000 (Invitrogen). Supernatants were collected 48 and 72 hours posttransfection, passed through a 0.45-mm nitrocellulose filter, and applied on target cells with polybrene (6μg/mL). Cells were re-infected the next day and, two days later, selected with puromycin for 72 hours (4μg/mL, Sigma).

To assess proliferation, cells were seeded in culture plates and incubated for 24h to allow attachment. Subsequently, seeding media were replaced with treatment media and cells were grown for varying lengths of time, at the end of which they were detached by trypsinization and collected. Cells were stained with trypan blue and counted using an automated cell counter (Invitrogen), which assessed the number of total and viable cells. In each experiment, initial seeding density was chosen to avoid confluence in fastest growth condition at the intended time-point.

For the bromodeoxyuridine (BrdU) incorporation assay (Cell Proliferation ELISA BrdU Kit from Roche), cells were seeded in 96-well plates (1,000 cells/well) and maintained as indicated in the figure legend for 72h. The assay was performed as per manufacturer’s instruction. Absorbance at 450nm (reference wavelength 690nm) was measured using a FluoStar Optima microplate reader (BMG Labtech).
Viable cell count or BrdU incorporation values for the indicated samples were normalized to those obtained for a vehicle treated cells (control). Data are expressed as % of inhibition relative to vehicle treated cells (control). Induction of cell death was estimated by Trypan blue staining and data are expressed as the ratio of trypan blue positive/total number of cells.

**Animals**

All protocols were approved by the McGill University Animal Care and Handling Committee. Male C57BL/6 mice were purchased from Charles River Laboratories (Saint-Constant, Québec, Canada) at 5–6 weeks of age. Animals were acclimatized for one week, after which, they were divided into two groups, one receiving a control diet and the other, a diet lacking serine and glycine (ser-/gly-) (Purchased from TestDiet). The control diet (formulation #: 5CC7) consisted of sucrose (25.9%), corn starch (41.8%), corn oil (5.0%) and the following amino acids: glutamine (1.00%), asparagine (1.00%) arginine (0.83%), histidine (0.49%), isoleucine (0.80%) leucine (1.20%), lysine (1.12%), methionine (0.60%), cystine (0.40%), phenylalanine (0.80%), tyrosine (0.40%), threonine (0.78%), tryptophan (0.20%), valine (0.80%), alanine (1.00%), aspartic acid (1.00%), glutamic acid (1.00%), glycine (0.99%), proline (1.00%), serine (1.00%). The ser-/gly- diet (customized from 5CC7) was formulated identically, however serine and glycine were omitted from the amino acid mixture. Animals were maintained on these diets for two weeks prior to the start of the allograft experiment in order to assess acceptance of new diets and weight gain indicative of adequate nutrition.
Allograft experiment

Animals were fed either control diet or serine and glycine deficient diet throughout the experiment. MC38 cells \(5 \times 10^5\) per animal were implanted by subcutaneous injection into left flank (day 0). Mice from each diet group were further subdivided into treatment and vehicle groups \(n = 8\). On day 5, treatment groups began receiving twice-daily intraperitoneal (IP) injections of 40mg/kg phenformin, a biguanide with greater \textit{in vivo} bioavailability than metformin; while control groups received twice-daily IP saline injections. In two-day intervals and on the sacrifice day, mice were weighed and tumors were measured by electronic calipers. On day 15, animals were sacrificed and their tumors were excised, and flash-frozen in liquid nitrogen. For GC/MS analyses, tumors were grinded in liquid nitrogen and 6-10mg was weighted in tubes kept on dry ice. Each tumor was extracted independently 3 times with 80\%(v/v) MeOH/milliQ water kept on dry ice. Suspensions were vortexed and sonicated for 10-20 minutes/\(4^\circ\)C (30sec ON and 30sec OFF, high setting, using Diagenode’s Bioruptor), vortexed and cleared by centrifugation \(21,000g, 10\text{min}/\(4^\circ\)C\). Supernatants were transferred to pre-chilled tubes and 800ng of the internal standard myristic acid-D\(_{27}\) diluted in pyridine was added to each sample. Samples were allowed to dry entirely in a Labconco CentriVap cold trap. GC/MS procedure (see GC/MS section) was carried out independently 3 times for the individual extractions.

Plasma serine and glycine.

Approximately 700µl of blood obtained by cardiac puncture from mice were transferred into BD Vacutainer Sodium Heparin collection tubes (BD) and plasma was separated by centrifugation. Plasma samples were flash frozen and stored at -80\(^\circ\)C. 2.5µL of plasma thawed
Shortly on ice was diluted in 300µL 80%(v/v) MeOH/milliQ water kept on dry ice. Samples were vortexed, sonicated and cleared by centrifugation (21,000 g, 10min/4°C). Supernatants were transferred to pre-chilled tubes and 800ng of the internal standard myristic acid-D_{27} diluted in pyridine was added to each sample. Samples were allowed to dry entirely in a Labconco CentriVap cold trap. The GC/MS procedure can be found in the GC/MS section.

**Immunoblots**

For protein analysis, cells were seeded and cultured in complete medium for 24h to obtain 30% confluence. Culture medium was replaced with indicated treatment media, and cells were cultured for various lengths of time; after which they were washed with ice-cold phosphate-buffered saline (PBS) and lysed in lysis buffer containing 10 mM Tris-HCl (pH 7.3), 150 mM NaCl, 1% sodium deoxycholate, 1% Triton X, 1 mmol/L EDTA, 10 mM β-glycerophosphate and 0.5 mmol/L NaF, supplemented with protease inhibitor pills (Roche). The crude lysates were centrifuged at 13,000 rpm for 15 min at 4°C and the resulting soluble fractions were isolated. Protein concentration was assessed using a bicinchoninic acid (BCA) protein assay kit (Thermo Scientific). Loading buffer was added to cleared lysates, which were subsequently boiled for 5 min. Samples were loaded into SDS-polyacrylamide gels, resolved by electrophoresis, transferred onto nitrocellulose membranes and probed using the indicated antibodies. Protein bands were visualized with ChemiDoc XRS+ system (Bio-Rad) using SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) or by using enhanced chemiluminescence (GE Healthcare). Antibodies for PHGDH was obtained from Novus Biologicals and Sigma (HPA021241) while those against phospho-S240/244 rpS6, phospho-T389 p70 S6K, phospho-T37/46 4E-BP1, phospho-T172 AMPKα, phospho-S79 ACC, rpS6, p70 S6K, 4E-BP1, AMPK,
ACC and β-actin were obtained from Cell Signaling Technology.

**Glucose consumption and lactate production assays**

Cells were seeded and cultured in complete medium for 24h in order to obtain 30% density. Medium was replaced with indicated treatment media, and cells were cultured for 24h. Subsequently, supernatant samples were collected. Cells were also collected, lysed and assayed for protein content. Measurement of glucose concentration in samples was done as previously described (29). Total consumption was calculated by subtracting results from baseline glucose concentration, measured in samples from media incubated in identical conditions, without cells. Lactate production was quantified using a commercial lactate assay kit (BioVision). Both glucose consumption and lactate production were normalized to protein content as described (30). The magnitude of changes in lactate production and glucose uptake over the 24 hour incubation was much larger than the changes in cell number or in protein content. Cells were collected, lysed, and protein content was determined using a BCA protein assay kit by multiplying protein concentration by total volume of lysate. Molar concentrations of metabolites (in mM) were multiplied by total media volume/well (2ml) and data expressed as nmol/μg of protein.

**Stable isotope tracing experiments**

MC38 grown up to 40% confluence in 35mm plates were subjected to $^{13}$C$_6$-glucose (CML-1396, Cambridge Isotope Laboratories, Inc.) or $^{13}$C$_5$-glutamine (CML-1822, Cambridge Isotope Laboratories, Inc.) pulse labeling along with metformin treatment, serine deprivation, or pyruvate supplementation for 24h (citrate isotopomer analyses), or pulsed for 6h in the presence
of $^{13}$C$_6$-glucose after the 24h incubations (serine isotopomer analyses). Basal medium used was RPMI 1640 lacking glucose, glutamine, glutamate, serine and glycine (Wisent) and supplemented with 2%(v/v) dialyzed FBS (Wisent). $^{13}$C$_6$-glucose and $^{13}$C$_5$-glutamine were used at half the final concentration, with unlabelled counterparts kept at 5.55mM glucose and 2mM glutamine (citrate isotopomer analyses) or at final 5.55mM for $^{13}$C$_6$-glucose (serine isotopomer analyses). When used as supplements, serine was added at 30 µg/mL and pyruvate was added at 1mM. Following incubations, cells were washed once with 2 mL 0.9%(w/v) NaCl/4°C on ice, then 300µL 80%(v/v) MeOH kept on dry ice was added to each well. Cells were removed from plates and transferred to pre-chilled tubes. MeOH quenching and harvest was repeated 1 or 2 times to ensure complete recovery. Suspensions were sonicated for 10-20 minutes/4°C (30 sec ON and 30 sec OFF, high setting, using Diagenode’s Bioruptor), vortexed and cleared by centrifugation (21,000g, 10min/4°C). Supernatants were transferred to pre-chilled tubes and 800ng of the internal standard myristic acid-D$_{27}$ diluted in pyridine was added to each sample. Samples were allowed to dry entirely in a Labconco CentriVap cold trap.

**GC/MS**

The GC/MS procedure was the same for plasmatic samples, tumor extracts and cell extracts. 30µL pyridine containing 10mg/mL methoxyamine hydrochloride (Sigma) was added to dried samples. Samples were vortexed and sonicated, cleared by centrifugation, and supernatants were heated at 70°C for 30min in GC/MS injection vials. Samples were further incubated for 1h after the addition of 70µL N-Methyl-N-tert-butyl dimethylsilyl trifluoroacetamide (MTBSTFA) (Sigma). 1µL was used per sample for
GC/MS analysis. GC/MS installations and softwares were all from Agilent. Our GC/MS methods are as previously described (31).

Mass Isotopomer Distribution Analysis

Ion integration was done with the Agilent Chemstation software. Integrations of all m+i ions, where m is the M-57 fragment of TBDMS derivatives and i, the number of possible $^{13}$C for this fragment, were transferred to a spreadsheet together with the integration of the internal standard myristic acid-D$_{27}$. A correction matrix was generated for each metabolite using an in-house algorithm adapted from (32). Integration values for a given metabolite were multiplied to the corresponding correction matrix to remove the abundances of naturally occurring isotopes that mask the labeling provided by exogenous $^{13}$C-substrates. Values obtained for a given metabolite correspond to proportional isotopomer enrichment, e.g. the proportion of a labeled fraction within the pool of total ions. In order to assess relative amounts of labelled ions, values of the proportional flux for a given metabolite were multiplied by the abundance of this metabolite previously divided by the integration of the internal standard and further divided by cell number. Values obtained are presented as normalized ion amounts, where the proportions of labelled ions are adjusted to the amount of the metabolite analyzed. For GC/MS data corrected on cell number, cells counts were obtained using 3 biological replicates and a TC10 counting device (Bio-Rad).

Statistical analyses

All experiments were independently performed at least 3 times unless specified. When biological replicates are shown, they are taken from a single experiment that was representative
of multiple independent experiments. Student’s *t*-tests were used for comparisons of individual treatments vs. control. Two-way analysis of variance (ANOVA) with Bonferroni’s post-tests was used for multiple comparisons. Statistical tests were performed with Microsoft Excel, GraphPad Prism or GraphPad InStat.

**Results**

**Cell Proliferation is influenced by interactions between serine availability, phosphoglycerate dehydrogenase expression, and metformin exposure.**

Either directly or through conversion to glycine, serine allows for the replenishment of one-carbon units, which play an important role in DNA methylation, maintenance of redox balance, and biosynthesis of nucleotides, phospholipids and other amino acids (33). Consequently, serine has been shown to be indispensable for the growth and proliferation of certain cancer cell lines, which must obtain it through uptake or through *de novo* biosynthesis from glucose. Thus, strategies combining serine deprivation and disruption of serine biosynthesis are antiproliferative *in vitro* (23,24,34). We investigated the impact of serine availability on the proliferative capacity of the human cancer cell lines H1299 and A549. Serine withdrawal exerted a substantial inhibitory effect on the proliferation of A549 cells, whereas it only weakly inhibited the proliferation of H1299 cells (Fig. 1A, B). This led us to hypothesize that these cell lines differ in their serine metabolism. As expected, relative to H1299 cells, A549 cells show reduced expression of D-3-phosphoglycerate dehydrogenase (PHGDH), the enzyme catalyzing the first step of the *de novo* serine synthesis pathway (Fig. 1C). To confirm that robust expression of PHGDH is key to sustaining proliferation in the absence of serine, we used MC38 colon cancer cells, previously demonstrated to be metformin sensitive *in vivo* (11). We depleted MC38 cells of
PHGDH using shRNA (>90% depletion as compared to control) (Fig. 2A). Serine deprivation had a drastic effect on cell proliferation in PHGDH depleted cells (Fig. 2B).

Cancer cells must coordinate the diversion of glucose metabolic flux into biosynthesis pathways to meet the macromolecular synthesis requirements for proliferation (21). Given the importance of serine for many biosynthetic pathways, its intracellular level may be an important indicator of cellular biosynthesis needs. In addition, serine deprivation has been shown to reduce the rate of glycolysis (25-27), which we hypothesized would increase sensitivity to the metabolic stress induced by biguanides. Therefore, we treated serine-deprived MC38 cells with metformin. In agreement with our hypothesis, serine withdrawal increased the antiproliferative effectiveness of otherwise sub-optimal doses of metformin (1-2.5mM) in MC38 cells (Fig. 1D). At 2.5mM, metformin did not greatly hinder proliferation of H1299 (Fig. 1A) or MC38 (Fig. 1E-F) cells in serine-replete conditions. This contrasts with results obtained with A549 cells (Fig. 1B) that are known to be sensitive to biguanides through a separate mechanism related to a lack of LKB1 expression (15). Under serine deprivation, metformin caused a marked inhibition of proliferation in both H1299 and MC38 cells that was not seen with either serine deprivation alone or metformin treatment alone (Fig. 1A and 1E-F, respectively). Proliferation curves for MC38 under serine deprivation combined with 2.5mM metformin revealed that arrest occurs within the first 24h of treatment and that neither serine deprivation nor the administration of 2.5mM metformin in the presence of serine affected the proliferation rate of MC38 cells (Fig. 1H). The observed decrease in cell number caused by metformin and serine withdrawal relative to control is primarily due to decreased proliferation (Fig. 1F), while cell survival was only modestly decreased under these conditions (Fig. 1G).
Importantly, although serine withdrawal or metformin treatment reduced proliferation of non-transformed, immortalized MCF10A cells, the combination did not significantly further suppress proliferation (Fig. 1E, right side). This is in direct contrast to the results obtained with transformed MC38 cells (Fig. 1E, left side). Moreover, serine deprivation did not bolster the anti-proliferative effects of metformin on primary prostate epithelial cells (PrEC) (Fig. 1I). These findings provide evidence that serine withdrawal potentiates the anti-proliferative effects of metformin on transformed cells to a greater extent than non-transformed cells, which is likely a consequence of reduced capacity of transformed cells to adapt to energetic stress.

Next, we investigated the effects of the attenuation of de novo serine biosynthesis on metformin-induced inhibition of proliferation in MC38 cells. (Fig. 2A). In the presence of serine, PHGDH depletion did not significantly potentiate the anti-proliferative effects of 2.5mM metformin as compared to control. Inhibition of proliferation induced by a combination of PHGDH depletion and metformin (~10% inhibition relative to metformin treated, control shRNA infected cells) was lower in magnitude compared to the combination of metformin and serine deprivation. This is likely due to the compensatory increase in serine uptake (see below) and/or the ability of remaining PHGDH to support low levels of serine biosynthesis. Of note, combined serine deprivation and PHGDH depletion induced dramatic inhibition of proliferation (over 95% of the control), which rendered determination of the combined effects of serine withdrawal, PHGDH depletion and metformin treatment unfeasible (Fig 2B). Collectively, these findings suggest that intracellular serine levels influence anti-neoplastic activity of biguanides.
Dietary restriction of serine and glycine increases *in vivo* effectiveness of phenformin as an antineoplastic agent.

It has been shown that a diet deficient in serine and glycine significantly reduces the serum levels of these amino acids in mice (25). We sought to extend our *in vitro* findings by creating a similar diet-induced serine and glycine deficiency in C57BL/6 mice bearing MC38 allografts and treating them with the more bioavailable biguanide phenformin (9). MC38 tumors grew rapidly regardless of the presence or absence of serine and glycine in the diet. Phenformin, dosed at 40mg/kg by intraperitoneal (IP) injection twice-daily did not impair tumor growth in mice fed the control diet. However, we observed a significant reduction in the growth rate and in the final size of the tumors in mice on the diet deficient in serine and glycine combined with phenformin treatment (Fig. 3A). All groups tolerated the combinations of diets and treatments administered, and constant weight gain was seen in all groups. To better understand the link between dietary amino acids and tumor growth, plasma and tumor serine and glycine levels were determined by GC/MS. Plasma of mice on the serine/glycine deficient diet showed reduced concentration of these amino acids (Fig.3B). Tumor serine and glycine levels were also reduced in the serine/glycine deprived groups at the conclusion of the experiment (Fig.3C). This observation provides pioneering evidence that dietary amino acid intake manipulation can potentiate the antineoplastic activity of biguanides *in vivo*.

**Metformin does not inhibit serine biosynthesis.**

Given that high expression of the serine biosynthesis enzyme PHGDH limits the impact of serine deprivation on cell proliferation (Fig.2B), we sought to determine whether the enhanced effects of metformin or phenformin under serine deprivation were due to inhibition of serine
biosynthesis. In order to evaluate the flux of glucose into serine under metformin and/or serine deprivation, we performed stable isotope tracer analysis using $^{13}$C$_6$-glucose (Fig.2C). $^{13}$C$_6$-glucose is converted to the glycolytic intermediate 3-phosphoglycerate (3-PG) m+3, which is further transformed into serine m+3 through the sequential reactions catalyzed by PHGDH, phosphoserine aminotransferase (PSAT) and 3-phosphoserine phosphatase (PSP). Serine is reversibly converted into glycine m+2, Thus, total serine isotopomers derived from $^{13}$C$_6$-glucose will contain m+1, m+2 and m+3 enrichments. Metformin did not inhibit $^{13}$C$_6$-glucose contribution to the serine pool, while serine deprivation drastically reduced it (Fig.2D). Metformin increased unlabeled serine (m+0) relative to control, and this effect was ablated by concomitant serine withdrawal, suggesting that metformin increases the uptake of exogenous serine. Metformin did not affect expression of PHGDH, which indicates that the effects of metformin on intracellular serine levels are not mediated by modulating expression of this enzyme in serine biosynthesis (Fig. 2E). Collectively, these data show that the decrease in proliferation upon metformin exposure in serine deprived MC38 cells cannot be explained by a decrease in de novo serine biosynthesis.

**Serine deficiency enhances the activity of biguanides in AMPK-independent manner.**

AMPK activation due to energetic stress leads to down-regulation of proliferation and other energy-consuming processes, thereby favoring cellular survival (35). Anti-proliferative effects of biguanides are in part mediated by AMPK-dependent inactivation of mTORC1 (10,36), whereas changes in intracellular serine levels have been shown to reduce the activity of mTORC1 in cell lines (27). Therefore, we explored the possibility that the enhancement of metformin-induced inhibition of proliferation by serine deprivation is mediated by the AMPK
and/or mTORC1 pathways. Serine withdrawal only marginally reduced the phosphorylation of mTOR effectors S6 kinase 1 (S6K1) and its downstream substrate ribosomal protein S6 (rpS6) in H1299 and MC38 as compared to control, whereas 2.5 mM metformin had no effect (Fig. 4A-B). In stark contrast, treatment with 2.5 mM metformin combined with serine deprivation resulted in further suppression of mTORC1 as judged by a strong reduction in S6K and rpS6 phosphorylation (Fig. 4A-C). The data show that the potentiation of the anti-proliferative effects of metformin by serine withdrawal is paralleled by decreased mTORC1 signaling.

We next determined if the effects of combination of serine withdrawal and metformin on mTORC1 are mediated by AMPK. To this end, we activated AMPK pharmacologically using AICAR while varying serine availability in MC38 cells. While 25μM AICAR had no effect on AMPK activation or ACC phosphorylation, both AMPK and ACC phosphorylation were stimulated with 50μM AICAR to levels comparable to those observed in 2.5 mM metformin treated cells, and this was paralleled by modest inhibition of mTORC1 as judged by slightly decreased phosphorylation of rpS6 (Fig. 5A, compare lanes 1 vs. 3 and 1 vs. 7). Moreover, the anti-proliferative effects of 50μM AICAR and 2.5 mM metformin were comparable. Surprisingly, although serine deprivation increased the inhibitory effects of both 50μM AICAR and 2.5 mM metformin on mTORC1 signaling (Figure 5A; compare lanes 3 and 4 and 7 and 8), serine withdrawal potentiated the anti-proliferative effects of metformin but not AICAR. (Fig. 5B). These results suggest that the potentiation of the effects of metformin by serine withdrawal is not mediated by AMPK or mTORC1.
To further corroborate these findings, we measured the effects of metformin and serine withdrawal on the proliferation of H1299 cells depleted of AMPKα1/2 by shRNA (Fig. 5C, D). These experiments revealed that similarly to AICAR, AMPKα1/2 subunit depletion does not affect the inhibition of proliferation by metformin in cells depleted of serine. Taken together, these findings show that serine withdrawal bolsters the anti-proliferative effects of biguanides independently of AMPK. This suggests that serine withdrawal and metformin exert their combinatory anti-proliferative effects by directly perturbing the metabolism of cancer cells.

**Serine deprivation reduces the upregulation of glycolysis and the shift in relative abundance of citric acid cycle metabolites induced by metformin.**

In the setting of energy stress due to inhibition of oxidative phosphorylation by biguanides, changes in metabolic fluxes occur. Primarily, oxygen consumption and glucose oxidation are decreased, while glycolytic flux to lactate is upregulated (18,20). Serine acts as a critical modulator of glycolysis (26). We therefore sought to explore the effects of serine deprivation and metformin treatment on glucose metabolism. We treated MC38 and H1299 cells with metformin for 24h and measured glucose consumption and lactate secretion. As expected, we observed substantial increases in glucose consumption and lactate secretion, indicative of upregulated glycolysis (Fig. 6A-B). Compared to cells in the serine-replete control condition, cells under serine deprivation exhibited a reduced rate of glycolysis (Fig. 6A-B). Furthermore, serine deprivation effectively inhibited the metformin-induced increase in glucose consumption, lactate secretion, and the lactate:pyruvate ratio (Fig. 6A-B, E). These results confirm that cells respond to metformin-induced energy stress by upregulating glycolysis, and demonstrate that serine deprivation is a potent inhibitor of this compensatory response. To further explore whether
serine depletion potentiates the anti-proliferative effects of biguanides by impeding the compensatory switch to glycolysis, we supplemented MC38 and H1299 cells with 1mM pyruvate. Given that in the presence of metformin, pyruvate entry into the citric acid cycle will be limited (15, 31), pyruvate supplementation will lead to the conversion of pyruvate into lactate by lactate dehydrogenase and the generation of NAD+ that is required for the activity of the glycolytic pathway. Accordingly, pyruvate alleviated the inhibitory effects of the combination of metformin and serine withdrawal on glycolysis (Fig. 6B), which was paralleled by rescue of proliferation (Fig. 6C). Hence, the combined inhibitory effect of metformin and serine withdrawal on cell proliferation can be explained at least in part by abrogation of metformin-induced compensatory switch to glycolysis in cells deprived of serine.

In addition to upregulating glycolysis, metformin alters the citric acid cycle due to accumulation of NADH as a consequence of complex I inhibition, promoting the usage of glutamine to support lipogenesis (37-40). Metformin was found to increase the α-ketoglutarate/citrate ratio by reducing glycolytic input into the mitochondria (41). Therefore, we assessed lactate, citrate and α-ketoglutarate levels in MC38 cells under serine deprivation and/or metformin treatment. Strikingly, metformin and serine deprivation had opposite effects on the concentration of these metabolites in cells, whereby serine withdrawal antagonized both the increase in lactate and α-ketoglutarate, and the decrease in citrate induced by metformin (Fig. 6D). Importantly, pyruvate rescued the levels of all three metabolites (Fig. 6D). As expected, metformin-treated MC38 cells showed an increase in the α-ketoglutarate/citrate ratio as compared to control (Fig. 6F). This effect was abolished by serine deprivation, and pyruvate partially restored the α-ketoglutarate/citrate ratio in metformin and serum depleted cells.
Considering these findings, we further studied the effects of metformin and serum withdrawal on citric acid cycle activity by monitoring citrate isotopomers with stable isotope tracer analysis using $^{13}$C$_6$-glucose or $^{13}$C$_5$-glutamine. Serine deprivation increased m+2 citrate derived from $^{13}$C-glucose (Fig.6G) and m+4 citrate derived from $^{13}$C$_5$-glutamine (Fig.6H), thereby supporting the observation that serine deprivation increases TCA cycle activity (25). In contrast, metformin dramatically reduced the flux of $^{13}$C$_6$-glucose into m+2 citrate (Fig.6G) while the flux of $^{13}$C$_5$-glutamine into m+5 citrate was maintained (Fig.6H). Importantly, serine deprivation alone led to an accumulation of $^{13}$C-glutamine-derived m+5 citrate, which was further increased when serine deprivation was combined with metformin treatment (Fig.6H). This finding, together with the serine withdrawal-induced decrease in α-ketoglutarate/citrate ratio (Fig.6F), suggests that serine deprivation alters the utilization of glutamine-derived citrate. Taken together, these findings suggest that serine withdrawal potentiates the anti-neoplastic effects of metformin at least in part by antagonizing compensatory metabolic pathways that are activated on exposure to biguanides.

Discussion
The hypothesis that the anti-diabetic biguanide metformin may be “repurposed” for indications in Oncology is receiving considerable attention, with more than 100 clinical trials involving metformin treatment for cancer presently underway (6). However, there are important gaps in knowledge with respect to the mechanisms of action. While metformin influences levels of circulating hormones in a manner that may reduce proliferation of certain cancers, these changes are modest in magnitude (5), and it is not established clinically that they are sufficient to
have a therapeutic effect. The possibility that biguanides act directly on cancer cells \textit{in vivo} is supported by many preclinical models (2,5-7,15,17). There is evidence that the direct antiproliferative actions of biguanides on cancer cells are a consequence of metabolic stress caused by inhibition of oxidative phosphorylation (2).

Prior work suggests that both host and tumor related factors influence the antineoplastic activity of biguanides. For example, cancers with baseline impairment of oxidative phosphorylation due to mutations in genes encoding proteins in respiratory complex I are particularly sensitive to biguanides, whereas high glucose levels attenuate the antiproliferative effects of biguanides by facilitating high rates of glycolysis, which can relieve the energy stress caused by biguanide-induced reduction in oxidative phosphorylation (17,18). We observed that sensitivity to biguanides \textit{in vitro} is significantly increased under conditions of serine deprivation, and extended this observation to an \textit{in vivo} model, where a level of biguanide exposure that is well tolerated but insufficient to achieve antineoplastic activity under control conditions inhibited tumor growth when mice were fed a diet deficient in glycine and serine. This diet was well tolerated and was not by itself associated with significant \textit{in vivo} tumor growth inhibition in the aggressive MC38 cancer cell model. In contrast, a recent report showed that dietary restriction of serine and glycine is sufficient to have an antiproliferative effect on the slower growing HCT116 cancer cell model (25).

Serine is directly involved in folate and methionine cycles, and is thus important for nucleotide biosynthesis, NADPH production and ROS clearance (42). We initially suspected a novel action of metformin as an inhibitor of serine biosynthesis to account for its enhanced
activity when serine is removed from culture medium, but this hypothesis was not supported by our metabolic studies. Rather, our results show that cell survival in the presence of biguanide-induced inhibition of oxidative phosphorylation is associated with increased glycolysis, and that under serine deprivation this compensatory increase in glycolysis does not take place (Fig. 7). This demonstrates a new context where the positive impact of serine on glycolysis (25-27,33) is important.

Inhibition of cancer growth by manipulation of dietary amino acids has previously been proposed (43,44), but leads to adverse effects of deficiency in essential amino acids. This contrasts with our approach, where a well-tolerated dietary restriction of two non-essential amino acids sensitizes cancer cells to biguanide treatment. Substantial inter-individual differences in circulating levels of glycine and serine exist between normal individuals (45), even in the absence of dietary interventions, and may influence the efficacy of biguanides as anti-neoplastic agents. Our findings indicate that characterizing and targeting compensatory metabolic pathways activated in response to biguanide-induced energy stress can identify strategies to improve the efficacy of these compounds as antineoplastic agents.

Acknowledgements

We thank Dr. Pnina Brodt for providing MC38 cells. H1299 with AMPKa1/2 stable knockdown and control cells were kindly provided by Dr. Russell Jones. We are grateful to Rhoda Lim for help with editing the manuscript and to Shannon McLaughlan for assistance.
References


11. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocrine-Related Cancer 2010;17:351-60.


Figure 1.
Serine deprivation enhances the antiproliferative effects of metformin in vitro.
H1299 (A) and A549 (B) cells were treated for 72h with vehicle (PBS) or metformin (2.5 mM), in media with or without 30 mg/L serine. Viable cells were counted. Data are shown as mean ± SEM (n = 3). *P<0.001. Results are representative of at least three independent experiments. (C) Cell lysates from H1299 and A549 cells treated as shown for 24h were immunoblotted using the indicated antibodies. (D) Metformin, at concentrations between 0.5 mM to 5 mM, substantially inhibited proliferation in MC38 cells cultured for 72h without serine. Data are shown as mean ± SEM (n = 3) (*P<0.01). (E-G) MC38 cells and MCF10A cells were treated as indicated for 72h. Proliferation was assessed by cell count (E) or BrdU incorporation (F) and cell death by trypan blue exclusion (G). Data are shown as mean± SEM (n = 3) (*P<0.05). (H) The combination of serine deprivation and metformin (2.5 mM) results in proliferation arrest within 24h of exposure in MC38. Cells were cultured as shown and were counted at the indicated times. Data are shown as mean ± SEM (n = 3) *P<0.05 compared to control. (I) Primary prostate epithelial cells (PrEC) were treated with metformin in the absence of serine for 48h; viable cells were counted. Effect of serine deprivation was compared with data obtained for H1299, MC38 and MCF10A cells in equivalent conditions. Data are shown as mean ± SEM (n = 3) (*P<0.05).

Figure 2.
PHGDH knockdown exacerbates the sensitivity to serine deprivation in MC38 cells but metformin does not inhibit serine biosynthesis.
(A) Immunoblot of cell lysates from MC38 cells stably expressing control or PHGDH shRNA, treated as indicated for 16h. (B) MC38 control or PHGDH depleted cells were treated as indicated for 72h and viable cells were counted. For each cell line (PHGDH shRNA or control shRNA) values were normalized to the vehicle control treated cells (set to 100%). Data are shown as mean ± SEM (n = 4).*P<0.01. (C) Schematic depicting the glucose carbon flow into serine biosynthesis. Unlabelled carbons (12C) are shown in white and 13C in black. 3-PG: 3-phosphoglycerate. (D) Stable isotope tracer analysis of serine in MC38 cells incubated with 13C6-glucose for 6h following the indicated 24h treatments. Each bar integrates serine isotopomer amounts and shows the relative metabolite levels per cell. Data are shown as mean ± SEM (n = 3 independent experiments). *P<0.05 (sum of glucose-derived isotopomers); #P<0.05 (m+0). (E) Immunoblot of MC38 cell lysates treated as indicated for 96h.

Figure 3.
Serine deprivation enhances the antiproliferative effects of phenformin in vivo.
(A) Serine and glycine free diet sensitizes tumors to an otherwise ineffective dose of phenformin. Mice (C57/BL6 male) were fed either control diet containing all amino acids, or isocaloric diet lacking serine and glycine. After 2 weeks on the respective diets, MC38 tumors were injected intraperitoneally (day 0). On day 5, mice were injected IP twice-daily with saline or 40 mg/kg phenformin, for 10 days (n = 8 for each diet / drug combination). Animals were sacrificed on day 15. Results are representative of two independent experiments. Data are shown as mean values of tumor volume ± SEM (*P<0.01). (B) Plasma serine and glycine concentrations in mice described in (A), were measured by GC/MS. Data are shown as mean ± SEM (n = 4 randomly picked mice from 1 experimental set). *P<0.05. (C) GC/MS assessment of serine and glycine levels in tumors of mice described in (A). Each data point represents the average metabolite abundance
determined by 3 independent extractions and GC/MS runs per tumor. Data are presented as mean ± SEM (6-7 animals per group). *P<0.05.

**Figure 4.**
**Under serine deprivation metformin decreases S6K and rpS6 phosphorylation.**
H1299 (A, C) or MC38 (B) cells were treated as indicated for 24h (A, B) or for the shown time periods (C). Immunoblots were performed using indicated antibodies. β-actin served as a loading control. Ser-: serine free media; Ser+: media with 30mg/L serine. Blots are representative of 3 independent experiments.

**Figure 5.**
**AMPK is dispensable for the effect of metformin under serine deprivation.**
(A) MC38 cells were treated as indicated for 24h and the levels of indicated proteins were determined by immunoblotting. β-actin served as a loading control. (B) MC38 cells were treated as indicated for 72h and viable cells were counted. (C) Loss of AMPK did not reduce the effect of metformin exposure with serine deprivation on viable cell count. AMPKα1/2 depleted (shRNA) or control H1299 cells were treated with metformin in the absence of serine for 72h and viable cells were counted. (D) Immunoblot of H1299 AMPKα1/2 and control shRNA expressing cells treated for 24h as indicated. β-actin served as a loading control.

**Figure 6.**
**Metabolic alterations underlie enhanced antineoplastic action of metformin under serine deprivation.**
(A) H1299 cells were treated for 24h as follows: Ser+: control; Ser-: serine-free; Met: metformin (2.5mM); Ser- Met: serine-free with metformin (2.5mM). Glucose consumption (white bars) and lactate production (black bars) were measured. Data are shown as mean ± SEM (n = 6). *P<0.001. (B) MC38 cells were treated as in (A), with or without a supraphysiological concentration of pyruvate (1mM). Glucose consumption (white bars) and lactate production (black bars) were measured. Data are shown as mean ± SEM (n = 6). *P<0.01 (C) MC38 cells were treated for 72h with metformin (2.5mM) in the presence or absence of serine, in the presence or absence of 1 mM pyruvate. Proliferation was determined by viable cell count and data is expressed as % of growth inhibition as compared to control. Data are shown as mean ± SEM (*P<0.01). (D) Intracellular lactate, citrate and α-ketoglutarate levels in MC38 treated for 24h as indicated were determined by GC/MS. Pyruvate addition (1mM) was simultaneous with other treatments. Data are shown as means ± SEM (n = 3 biological replicates). (E) Intracellular lactate to pyruvate ratio, which indicates LDH activity, in MC38 was determined by GC/MS. Data are shown as mean ± SEM (n = 3 independent experiments). *P<0.05. (F) α-ketoglutarate (α-KG) to citrate ratio, indicator of glutamine-dependent reversal of citric acid cycle, in MC38 cells was determined by GC/MS. Pyruvate addition (1mM) was simultaneous to other indicated treatments. Data are shown as mean ± SEM (n = 3 biological replicates). *P<0.05. (G) Stable isotope tracer analyses of citrate in MC38 cells treated as indicated and incubated with 13C6-glucose for 24h. Each bar integrates principal isotopomer ion amounts and shows the relative metabolite present per cell. Data are shown as mean ± SEM (n=3 biological replicates). *P<0.05. (H) Stable isotope tracer analyses of citrate in MC38 cells treated as indicated and incubated with 13C5-glutamine. Each bar integrates principal isotopomer ion amounts and shows the relative metabolite present per cell. M+5 reflects reverse citric acid cycle cycling through
reductive carboxylation, while m+4 reflects forward citric acid cycle cycling. Data are shown as mean ± SEM (n=3 biological replicates). *P<0.05.

Figure 7.
Schematic of the proposed mechanism by which serine deprivation interferes with biguanide-induced metabolic remodeling.
(Left) Biguanide-induced reduction in oxidative phosphorylation leads to (a) a compensatory increase in glycolysis with augmentation of glucose uptake and lactate production and (b) reductive carboxylation in the citric acid cycle. These effects on the citric acid cycle are reflected by an increase in the alpha-ketoglutarate (α-KG) to citrate ratio. (Right) Serine withdrawal counteracts these compensatory metabolic responses to biguanides, resulting in enhanced antineoplastic activity.
Serine (30 mg/L) : Metformin (2.5 mM) :

![Graphs showing cell viability and metabolic changes.](Image)

**Figure 1**

**A** H1299  
- Bar graphs showing cell viability (Viable Cells x10^6) for Control, Metformin (2.5 mM), Serine (+), and Serine (-) conditions.

**B** A549  
- Bar graphs showing cell viability (Viable Cells x10^6) for Control, Metformin (2.5 mM), Serine (+), and Serine (-) conditions.

**C**  
- Western blots showing PHGDH and β-Actin expression levels under Serine (30 mg/L) and Metformin (2.5 mM) conditions.

**D** MC38  
- Line graph showing Serine+ and Serine- viable cell counts (Viable Cells x10^6) over Metformin concentrations (0-5 mM).

**E** MC38  
- Bar graph showing Viable cell count (% of control) for Control, Metformin (2.5 mM), Serine (+), and Serine (-) conditions.

**F** MC38  
- Bar graph showing BrdU incorporation (% of control) for Control, Metformin (2.5 mM), Serine (+), and Serine (-) conditions.

**G** MC38  
- Bar graph showing Trypan blue positive (% of total cell count) for Control, Metformin (2.5 mM), Serine (+), and Serine (-) conditions.

**H** MC38  
- Line graphs showing Viable Cells x10^6 and Viable cell count (% of metformin treated control) over Time (days).

**I**  
- Bar graph showing Viable cell count (% of metformin treated control) for Control, Metformin (2.5 mM), H1299, MC38, MCF10A, and PrEC conditions.

* indicates statistical significance.
**Figure 2**

**A**

<table>
<thead>
<tr>
<th>shRNA ctr</th>
<th>shRNA PHGDH</th>
</tr>
</thead>
</table>

Serine (30 mg/L): + - + - + - + - +

Metformin (2.5 mM): - - + + - - + +

**B**

<table>
<thead>
<tr>
<th>Metformin (2.5 mM)</th>
<th>shRNA ctr</th>
<th>shRNA PHGDH</th>
</tr>
</thead>
</table>

Ser +: * * * *
Ser -: * *

**C**

**D**

**E**

<table>
<thead>
<tr>
<th>Serine (30 mg/L)</th>
<th>Metformin (2.5 mM)</th>
</tr>
</thead>
</table>

Downloaded from cancerres.aacrjournals.org on June 6, 2017. © 2014 American Association for Cancer Research.
Figure 3

A

- Control diet + Saline (1)
- Control diet + Phenformin (2)
- Ser/-Gly diet + Saline (3)
- Ser/-Gly diet + Phenformin (4)

(B) Plasma

<table>
<thead>
<tr>
<th></th>
<th>Serine</th>
<th>Glycine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-Ser/-Gly</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

P = 0.0674

C

- Tumor

<table>
<thead>
<tr>
<th></th>
<th>Serine</th>
<th>Glycine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-Ser/-Gly</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Figure 4**

A  

<table>
<thead>
<tr>
<th>H1299</th>
<th>B</th>
<th>MC38</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="p-p70 S6K" /></td>
<td><img src="image2" alt="p-rpS6" /></td>
<td><img src="image3" alt="p-rpS6" /></td>
</tr>
<tr>
<td><img src="image4" alt="p70 S6K" /></td>
<td><img src="image5" alt="rpS6" /></td>
<td></td>
</tr>
<tr>
<td><img src="image6" alt="p-rpS6" /></td>
<td><img src="image7" alt="β-actin" /></td>
<td></td>
</tr>
<tr>
<td><img src="image8" alt="rpS6" /></td>
<td></td>
<td></td>
</tr>
<tr>
<td><img src="image9" alt="β-actin" /></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Serine (30 mg/L): + - + -
Metformin (2.5 mM): - - + +

C  

<table>
<thead>
<tr>
<th>H1299</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image10" alt="Control" /></td>
</tr>
<tr>
<td><img src="image12" alt="Ser + Ser -" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PHGDH</th>
<th>p-rpS6</th>
<th>rpS6</th>
<th>β-actin</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image14" alt="Time (h): 1 3 6 1 3 6" /></td>
<td><img src="image15" alt="Time (h): 1 3 6 1 3 6" /></td>
<td><img src="image16" alt="Time (h): 1 3 6 1 3 6" /></td>
<td><img src="image17" alt="Time (h): 1 3 6 1 3 6" /></td>
</tr>
</tbody>
</table>
Figure 5

A

<table>
<thead>
<tr>
<th>Serine (30 mg/L)</th>
<th>Metformin (2.5 mM)</th>
<th>AICAR (25μM)</th>
<th>AICAR (50μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>p-AMPKα</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMPK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-ACC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-rpS6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rpS6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

![Bar chart showing viable cell count for different conditions](image)

C

![Graph showing viable cell count for different shRNA conditions](image)

D

![Western blot images showing AMPK and β-actin expression](image)
Serine Deprivation Enhances Anti-neoplastic Activity of Biguanides

Nader Toban, Simon-Pierre Gravel, Laura Hulea, et al.

*Cancer Res* Published OnlineFirst November 6, 2014.

**Updated version**
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-2643-T

**Author Manuscript**
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.